Cargando…

A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio

BACKGROUND: Plenty of studies have demonstrated the prognostic value of various inflammation-based indexes in cancer. This study was designed to investigate the prognostic value of the C-reactive protein/albumin (CRP/Alb) ratio in esophageal squamous cell carcinoma. METHODS: A retrospective study of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiao-li, Wang, Feng-hua, Zhang, Dong-sheng, Qiu, Miao-zhen, Ren, Chao, Jin, Ying, Zhou, Yi-xin, Wang, De-shen, He, Ming-ming, Bai, Long, Wang, Feng, Luo, Hui-yan, Li, Yu-hong, Xu, Rui-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423167/
https://www.ncbi.nlm.nih.gov/pubmed/25934640
http://dx.doi.org/10.1186/s12885-015-1379-6
_version_ 1782370164232159232
author Wei, Xiao-li
Wang, Feng-hua
Zhang, Dong-sheng
Qiu, Miao-zhen
Ren, Chao
Jin, Ying
Zhou, Yi-xin
Wang, De-shen
He, Ming-ming
Bai, Long
Wang, Feng
Luo, Hui-yan
Li, Yu-hong
Xu, Rui-hua
author_facet Wei, Xiao-li
Wang, Feng-hua
Zhang, Dong-sheng
Qiu, Miao-zhen
Ren, Chao
Jin, Ying
Zhou, Yi-xin
Wang, De-shen
He, Ming-ming
Bai, Long
Wang, Feng
Luo, Hui-yan
Li, Yu-hong
Xu, Rui-hua
author_sort Wei, Xiao-li
collection PubMed
description BACKGROUND: Plenty of studies have demonstrated the prognostic value of various inflammation-based indexes in cancer. This study was designed to investigate the prognostic value of the C-reactive protein/albumin (CRP/Alb) ratio in esophageal squamous cell carcinoma. METHODS: A retrospective study of 423 cases with newly diagnosed esophageal squamous cell carcinoma was conducted. We analyzed the association of the CRP/Alb ratio with clinicopathologic characteristics. The prognostic value was explored by univariate and multivariate survival analysis. In addition, we compared the discriminatory ability of the CRP/Alb ratio with other inflammation-based prognostic scores by evaluating the area under the receiver operating characteristics curves (AUC), including the modified Glasgow Prognostic Score (mGPS), neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR). RESULTS: The optimal cut-off value was identified to be 0.095 for the CRP/Alb ratio. A higher level of the CRP/Alb ratio was associated with larger tumor size (P < 0.001), poorer differentiation (P = 0.019), deeper tumor invasion (P = 0.003), more lymph node metastasis (P = 0.015), more distant metastasis (P < 0.001) and later TNM stage (P < 0.001). The CRP/Alb ratio was identified to be the only inflammation-based prognostic score with independent association with overall survival by multivariate analysis (P = 0.031). The AUC value of the CRP/Alb ratio was higher compared with the NLR and PLR, but not mGPS at 6, 12 and 24 months of follow-up. In addition, the CRP/Alb ratio could identify a group of patients with mGPS score of 0 who had comparable overall survival with those with mGPS score of 1. CONCLUSIONS: The CRP/Alb ratio is a novel but promising inflammation-based prognostic score in esophageal squamous cell carcinoma. It is a valuable coadjutant for the mGPS to further identify patients’ survival differences. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1379-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4423167
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44231672015-05-08 A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio Wei, Xiao-li Wang, Feng-hua Zhang, Dong-sheng Qiu, Miao-zhen Ren, Chao Jin, Ying Zhou, Yi-xin Wang, De-shen He, Ming-ming Bai, Long Wang, Feng Luo, Hui-yan Li, Yu-hong Xu, Rui-hua BMC Cancer Research Article BACKGROUND: Plenty of studies have demonstrated the prognostic value of various inflammation-based indexes in cancer. This study was designed to investigate the prognostic value of the C-reactive protein/albumin (CRP/Alb) ratio in esophageal squamous cell carcinoma. METHODS: A retrospective study of 423 cases with newly diagnosed esophageal squamous cell carcinoma was conducted. We analyzed the association of the CRP/Alb ratio with clinicopathologic characteristics. The prognostic value was explored by univariate and multivariate survival analysis. In addition, we compared the discriminatory ability of the CRP/Alb ratio with other inflammation-based prognostic scores by evaluating the area under the receiver operating characteristics curves (AUC), including the modified Glasgow Prognostic Score (mGPS), neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR). RESULTS: The optimal cut-off value was identified to be 0.095 for the CRP/Alb ratio. A higher level of the CRP/Alb ratio was associated with larger tumor size (P < 0.001), poorer differentiation (P = 0.019), deeper tumor invasion (P = 0.003), more lymph node metastasis (P = 0.015), more distant metastasis (P < 0.001) and later TNM stage (P < 0.001). The CRP/Alb ratio was identified to be the only inflammation-based prognostic score with independent association with overall survival by multivariate analysis (P = 0.031). The AUC value of the CRP/Alb ratio was higher compared with the NLR and PLR, but not mGPS at 6, 12 and 24 months of follow-up. In addition, the CRP/Alb ratio could identify a group of patients with mGPS score of 0 who had comparable overall survival with those with mGPS score of 1. CONCLUSIONS: The CRP/Alb ratio is a novel but promising inflammation-based prognostic score in esophageal squamous cell carcinoma. It is a valuable coadjutant for the mGPS to further identify patients’ survival differences. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1379-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-02 /pmc/articles/PMC4423167/ /pubmed/25934640 http://dx.doi.org/10.1186/s12885-015-1379-6 Text en © Wei et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wei, Xiao-li
Wang, Feng-hua
Zhang, Dong-sheng
Qiu, Miao-zhen
Ren, Chao
Jin, Ying
Zhou, Yi-xin
Wang, De-shen
He, Ming-ming
Bai, Long
Wang, Feng
Luo, Hui-yan
Li, Yu-hong
Xu, Rui-hua
A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
title A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
title_full A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
title_fullStr A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
title_full_unstemmed A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
title_short A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
title_sort novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the c-reactive protein/albumin ratio
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423167/
https://www.ncbi.nlm.nih.gov/pubmed/25934640
http://dx.doi.org/10.1186/s12885-015-1379-6
work_keys_str_mv AT weixiaoli anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT wangfenghua anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT zhangdongsheng anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT qiumiaozhen anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT renchao anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT jinying anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT zhouyixin anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT wangdeshen anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT hemingming anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT bailong anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT wangfeng anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT luohuiyan anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT liyuhong anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT xuruihua anovelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT weixiaoli novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT wangfenghua novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT zhangdongsheng novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT qiumiaozhen novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT renchao novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT jinying novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT zhouyixin novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT wangdeshen novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT hemingming novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT bailong novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT wangfeng novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT luohuiyan novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT liyuhong novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio
AT xuruihua novelinflammationbasedprognosticscoreinesophagealsquamouscellcarcinomathecreactiveproteinalbuminratio